Details for Patent: 10,239,846
Which drugs does patent 10,239,846 protect, and when does it expire?
Patent 10,239,846 protects ZEPOSIA and is included in one NDA.
This patent has thirty-three patent family members in eight countries.
Summary for Patent: 10,239,846
| Title: | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis |
| Abstract: | Compounds that selectively modulate the sphingosine 1 phosphate receptor are provided including compounds which modulate subtype 1 of the S1P receptor. Methods of chiral synthesis of such compounds are provided. Uses, methods of treatment or prevention and methods of preparing inventive compositions including inventive compounds are provided in connection with the treatment or prevention of diseases, malconditions, and disorders for which modulation of the sphingosine 1 phosphate receptor is medically indicated. |
| Inventor(s): | Esther Martinborough, Marcus F. Boehm, Adam Richard Yeager, Junko Tamiya, Liming Huang, Enugurthi Brahmachary, Manisha Moorjani, Gregg Alan Timony, Jennifer L. Brooks, Robert Peach, Fiona Lorraine Scott, Michael Allen Hanson |
| Assignee: | Receptos LLC |
| Application Number: | US15/406,128 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 10,239,846 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 10,239,846
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol | ZEPOSIA | ozanimod hydrochloride | CAPSULE;ORAL | 209899-001 | Mar 25, 2020 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC) IN ADULTS | ⤷ Start Trial | ||||
| Bristol | ZEPOSIA | ozanimod hydrochloride | CAPSULE;ORAL | 209899-002 | Mar 25, 2020 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC) IN ADULTS | ⤷ Start Trial | ||||
| Bristol | ZEPOSIA | ozanimod hydrochloride | CAPSULE;ORAL | 209899-003 | Mar 25, 2020 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC) IN ADULTS | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,239,846
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2010319982 | ⤷ Start Trial | |||
| Australia | 2010319983 | ⤷ Start Trial | |||
| Australia | 2010320041 | ⤷ Start Trial | |||
| Brazil | 112012011427 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
